Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies ...

Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ...

D. Boral Capital reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR – Free Report) in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a ...

A new study conducted at the Scojen Institute for Synthetic Biology at Reichman University's Dina Recanati School of Medicine ...

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) has earned a consensus recommendation of “Buy” from the eight research ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus’ fusion protein — the target of ...

Researchers in India discovered novel hMPV lineages A2.2.1 and A2.2.2, emphasizing their role in pediatric respiratory ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

The recent findings of Waldo et al. 1 demonstrate that the fusion of the green fluorescent protein (GFP) to insoluble proteins dramatically reduces its folding ability in prokaryotic cells.